EcoDrugPlus

Platelet Activating Factor Receptor

Ensembl ID : ENSOKIG00005010406
Gene Symbol: PTAFR
1 Cross references
209 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSOKIG00005003514
Gene Symbol: PTAFR
1 Cross references
214 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSOKIG00005003530
Gene Symbol: PTAFR
1 Cross references
214 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSOKIG00005014183
Gene Symbol: PDGFRA
3 Cross references
197 Possible Orthologues:

Platelet-Activating Factor Acetylhydrolase

Ensembl ID : ENSOKIG00005031486
Gene Symbol: LOC109866325
2 Cross references
196 Possible Orthologues:

Platelet-Activating Factor Acetylhydrolase-Like

Ensembl ID : ENSOKIG00005034911
Gene Symbol: LOC109900931
3 Cross references
197 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Alpha-Like

Ensembl ID : ENSOKIG00005049586
Gene Symbol: LOC109902718
3 Cross references
198 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta

Ensembl ID : ENSOKIG00005038087
Gene Symbol: LOC109873120
2 Cross references
174 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSOKIG00005013066
Gene Symbol: LOC109864648
2 Cross references
192 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSOKIG00005047175
Gene Symbol: LOC109905074
3 Cross references
192 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSOKIG00005029808
Gene Symbol: PLK1
1 Cross references
186 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSOKIG00005026236
Gene Symbol: PLK1
1 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).